Plain-English translation of NCT06366425 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This study is testing whether combining two non-invasive tests—a blood test called the FIB-4 score and an ultrasound scan of the liver called Fibroscan—can better detect liver fibrosis (scarring) in people at risk. Researchers believe that using both tests together will be more accurate than using just one, helping catch liver disease earlier in people who may not know they have it.
Liver disease is becoming more common, but many people have it without knowing. Early detection can prevent serious complications like liver failure or cancer. This study aims to find the best way to screen people at risk using simple, non-invasive tests rather than requiring a painful liver biopsy.
You would have a blood test to calculate your FIB-4 score, which measures liver function using routine blood work. If your score suggests possible advanced liver scarring, you would then receive a Fibroscan—a painless ultrasound scan of your liver that takes about 5–10 minutes. The entire process is non-invasive, meaning no needles or biopsies beyond the initial blood draw.
AI-generated summary from trial data · Jun 22, 2026 · Not medical advice
France
Collaborators
On-call medical home (MMG) Clermont-Hérault, Medical office Montpeyroux
Enrollment target
~260 participants
Started
September 2024
Primary completion
April 2025
Age range
40 Years and older
Last updated on clinicaltrials.gov in June 2026.